Adjuvant Trastuzumab for Breast Cancer: An Increasingly Common Ethical and Economic Conundrum

BMJ
doi 10.1136/bmj.331.7526.1202-b
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Cost Considerations in Determining the Affordability of Adjuvant Trastuzumab in Breast Cancer

South African Medical Journal
Medicine
2016English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Trastuzumab-Resistance and Breast Cancer

2011English

Progress in Adjuvant Chemotherapy for Breast Cancer: An Overview

BMC Medicine
Medicine
2015English

Trastuzumab-Containing Regimens for Metastatic Breast Cancer

Cochrane Database of Systematic Reviews
2014English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adjuvant Chemotherapy for Early Breast Cancer.

BMJ
1983English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy